In the last trading session, 3.67 million Royalty Pharma plc (NASDAQ:RPRX) shares changed hands as the company’s beta touched 0.49. With the company’s per share price at $34.25 changed hands at $0.23 or 0.68% during last session, the market valuation stood at $19.26B. RPRX’s last price was a premium, traded about 0.15% off its 52-week high of $34.20. The share price had its 52-week low at $24.05, which suggests the last value was 29.78% up since then.
Analysts gave the Royalty Pharma plc (RPRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.44. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RPRX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
Royalty Pharma plc (NASDAQ:RPRX) trade information
Instantly RPRX was in green as seen at the end of in last trading. With action 2.70%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 34.26%, with the 5-day performance at 2.70% in the green. However, in the 30-day time frame, Royalty Pharma plc (NASDAQ:RPRX) is 5.06% up.
The consensus price target for the stock as assigned by Wall Street analysts is 51, meaning bulls need an upside of 32.84% from its current market value. According to analyst projections, RPRX’s forecast low is 28 with 51 as the target high. To hit the forecast high, the stock’s price needs a -48.91% plunge from its current level, while the stock would need to tank 18.25% for it to hit the projected low.
Royalty Pharma plc (RPRX) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -21.51%. The 2025 estimates are for Royalty Pharma plc earnings to increase by 6.93%, but the outlook for the next 5-year period is at 10.77% per year.
RPRX Dividends
Royalty Pharma plc is expected to release its next quarterly earnings report in June. The 2.51% annual yield figure for the share gives it an annual dividend of 0.86. It is important to note, however, that the 2.51% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
Royalty Pharma plc (NASDAQ:RPRX)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.4303% or 38.02 million shares worth $1.0 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund. With 11.74 shares estimated at $402.14 million under it, the former controlled 2.79% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund held about 1.93% of the shares, roughly 8.12 shares worth around $278.1 million.
